Drug Profile
Research programme: low dose naltrexone-based therapeutic - Premier Biomedical
Alternative Names: Feldetrex®Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Premier Biomedical
- Class Analgesics; Cyclopropanes; Morphinans; Small molecules
- Mechanism of Action Neurotransmitter modulators; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain injuries; Fibromyalgia; Multiple sclerosis; Neuropathic pain; Substance-related disorders
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for research development in Brain injuries in USA (PO)
- 28 Jul 2022 No recent reports of development identified for research development in Fibromyalgia(Adjunctive treatment) in USA (PO)
- 28 Jul 2022 No recent reports of development identified for research development in Multiple-sclerosis(Adjunctive treatment) in USA (PO)